Long term follow-up of transsphenoidal surgery for the treatment of Cushing's disease in childhood.
Transsphenoidal removal of pituitary adenomas has become the accepted treatment for Cushing's disease. As Cushing's disease is rare in childhood, few reports describe extended follow-up after transsphenoidal surgery for this disease in children. Twenty-two patients less than 19 yr of age were diagnosed with Cushing's disease by standard testing. All patients underwent transsphenoidal surgery (TSS) as primary treatment at Mayo Clinic between 1975 and 1990. Follow-up was available in all patients and averaged 6.7 yr. Adenomas were identified pathologically in 19 patients and visualized by the surgeon in the remainder. There was 1 macroadenoma. Ten patients are considered cured with a mean follow-up of 5.5 yr. Five patients had evidence of persistent disease within 6 months of TSS and required further treatment. Seven patients had remission lasting greater than 6 months with subsequent relapse (mean time to recurrence, 7.0 yr). In children treated with TSS for Cushing's disease, the rate of cure with extended follow-up is only approximately 50%. This rate is much lower than that in adults and may indicate that Cushing's disease is more aggressive in childhood. As TSS is associated with low morbidity, we feel it is still the treatment of choice for Cushing's disease in children.
Leinung
M C
MC
Department of Pediatrics, Mayo Clinic, Rochester, Minnesota 55905, USA.
Kane
L A
LA
Scheithauer
B W
BW
Carpenter
P C
PC
Laws
E R
ER
Zimmerman
D
D
D000236:Adenoma / Q000097:blood; D000293:Adolescent; D002648:Child; D003480:Cushing Syndrome / Q000097:blood / Q000503:physiopathology / Q000601:surgery*; D003907:Dexamethasone; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007016:Hypophysectomy / Q000379:methods; D008297:Male; D010911:Pituitary Neoplasms / Q000097:blood; D012008:Recurrence; D012737:Sex Factors; D013997:Time Factors; D016896:Treatment Outcome
D003907:Dexamethasone; D006854:Hydrocortisone